Speakers – uventia https://www.uventia.com Custom webinars for Pharma, Biotech, and Medical Devices Thu, 09 Jul 2026 15:33:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.3 https://www.uventia.com/wp-content/uploads/2025/01/cropped-uventia-logo-1-32x32.png Speakers – uventia https://www.uventia.com 32 32 Jayrajsinh Sarvaiya https://www.uventia.com/speaker/jayrajsinh-sarvaiya/ Wed, 15 Jul 2026 13:21:24 +0000 https://www.uventia.com/?post_type=speaker&p=13135
Jayrajsinh Sarvaiya

Prof. (Dr.) Jayrajsinh Sarvaiya

Dean – Forensic Pharmacy; Centre Head – Drug & Food Forensics

NFSU

Prof. (Dr.) Jayrajsinh Sarvaiya is among India’s most experienced specialists in contamination investigation and CAPA implementation, built on the creation of product contact and non-contact part contaminant libraries. At the National Forensic Sciences University (Government of India), he serves as Dean of Forensic Pharmacy and Center Head for Drug and Food Forensics, and has supported more than 250 pharmaceutical plants on visual inspection subject-matter support, complex generics characterization, and contamination investigation. His team received the CPHI India 2025 award for noteworthy contribution to the pharmaceutical industry through niche areas of service.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 2: September 29th, 2026

SESSION: Bridging Visual Inspection and Contamination Control

◆  Visual inspection as a contamination-control input, not just a release gate: how reject data, defect categories and trends feed the Annex 1 Contamination Control Strategy (CCS).

◆  Closing the loop from detection to source: forensic triage of intrinsic, extrinsic and inherent particles using investigative microscopy, SEM-EDS, FTIR and Raman.

◆  Contact and non-contact parts libraries: building a facility-specific contaminant fingerprint database so an event is matched in hours rather than weeks.

◆  Feeding investigation findings back into qualification: casework-derived defects in Knapp kits and AVI challenge sets, so detection is qualified against the contaminants the site actually generates.

◆  From identification to defensible CAPA: linking particle identity to a process source, lot-impact assessment and corrective action that withstands regulatory scrutiny.

]]>
Matthias Kahl https://www.uventia.com/speaker/matthias-kahl/ Thu, 09 Jul 2026 15:33:58 +0000 https://www.uventia.com/?post_type=speaker&p=13120
Matthias Kahl

Matthias Kahl

Head of R&D and Lab Services

Wilco

Dr. Matthias Kahl leads R&D and LabServices at WILCO AG, shaping the company’s innovation roadmap and advancing next-generation technologies. Since joining WILCO in 2017, he has been instrumental in driving new technology development and aligning R&D initiatives with long-term business goals. Matthias holds a Ph.D. in optics and laser technology from the University of Konstanz and a degree in physics from the University of Erlangen, with a specialization in solid-state physics and metrology. Prior to WILCO, he helped scale high-precision laser material processing operations as Deputy Development Manager.
Beyond product development, he plays a key role in innovation strategy, intellectual property management, and quality excellence — building a strong foundation for sustainable growth and market leadership.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: Doing more with less: A comparative case study of rule-based automation vs. AI with additional focus on resource requirements

◆  Initial effort needed to achieve high performance in inspection systems.

◆  Case study for difficult to inspect feature.

◆  Spotlight on the resource effort needed for optimization and changes in production.

]]>
Poorti Mohindroo https://www.uventia.com/speaker/poorti-mohindroo/ Fri, 03 Jul 2026 08:40:48 +0000 https://www.uventia.com/?post_type=speaker&p=13104
Poorti Mohindroo

Poorti Mohindroo

Managing Director

Forensic Technological Innovation

Dr. Poorti Mohindroo is Managing Director of Forensic Technological Innovation (FTI), the DPIIT-recognised venture incubated at National Forensic Sciences University (NFSU) — an Institute of National Importance. With eight years of experience, she specializes in converting successful R&D prototypes from lab to market. She previously worked with NFSU’s CoE–FTF on pharmaceutical contamination investigation and Q3 characterization of complex generics, and now heads FTI, developing forensic-grade Knapp kits, AVI qualification challenge sets, and CCIT verification standards trusted by 200+ pharmaceutical clients worldwide. A PhD, ISO-qualified lead auditor, and inventor of one utility and one design patent, she has authored four publications and advances both scientific and commercial fronts.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: Qualifying Detection on the Hardest-to-Inspect Parenterals: Closing the False-Reject Gap

◆  Why AVI qualification can’t be extrapolated: USP <1790> requires detection be proven equal to or better than qualified manual inspection under representative conditions, yet a system validated on clear liquids has demonstrated nothing about the formats that resist inspection.

◆  Where inspection gets hard: how normal variation in lyophilized cakes and powders, suspensions, emulsions, biologics, and amber/molded-glass or polymer containers mimics true defects, a primary driver of the 10–30% false-reject rates reported for difficult-to-inspect products.

◆  Challenge sets that reflect the line, not the lab: format-specific defect design across the visible range (100–3000 µm), with verified morphology and exact placement, derived from real forensic contamination casework rather than generic catalogs.

◆  From qualification to yield and audit-readiness: demonstrating probability of detection per USP <790>/<1790> and EU GMP Annex 1, producing IQ/OQ/PQ evidence with the traceability regulators expect.

]]>
Max Scheible https://www.uventia.com/speaker/max-scheible/ Fri, 26 Jun 2026 15:07:07 +0000 https://www.uventia.com/?post_type=speaker&p=13084
Max Scheible

Max Scheible

Director Visual Inspection & Technology Transfer

Vetter

Dr. Max Scheible is Director of Visual Inspection & Technology Transfer (Development Services) at Vetter Pharma-Fertigung in Ravensburg, Germany. He holds a PhD in Physics from the Technical University of Munich and spent several years in academia before joining Vetter in 2018.
In his current role, he is responsible for the implementation of visual inspection processes and provides subject matter expertise in inspection methods and technologies.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: A CDMO View on Automated Visual Inspection

◆  The growing role of Automated Visual Inspection (AVI) in quality, efficiency, and compliance.

◆  Key challenges of AVI implementation from a CDMO perspective.

◆  Balancing standardisation with customer-specific flexibility.

◆  Managing regulatory expectations, internal quality requirements, and client demands.

◆  Practical aspects of AVI governance and validation.

◆  Collaboration with customers and technology suppliers throughout the system lifecycle.

◆  Lessons learned from implementation, operation, and continuous improvement of AVI systems.

]]>
Oliver Germershaus https://www.uventia.com/speaker/oliver-germershaus/ Sat, 13 Jun 2026 07:15:45 +0000 https://www.uventia.com/?post_type=speaker&p=12886
Oliver Germershaus

Oliver Germershaus

Professor for Pharmaceutical Technology of Macromolecular Drugs

FHNW

Oliver Germershaus is Professor of Pharmaceutics of Macromolecular Drugs and Head of the Institute of Pharmaceutical Technology and Biotechnology at the University of Applied Sciences Northwestern Switzerland. His research focus areas include formulation and processing of biologics, development of drug delivery systems, and parenteral packaging and device development. In recent years, he has placed special emphasis on developing novel particle standards designed to match the appearance and behavior of inherent particles.
Germershaus is co-founder and chief scientific officer of Partiris, a Swiss startup that focuses on developing and manufacturing specialized pharmaceutical standard materials, such as particle standards for manual and automatic visual inspection.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 2: September 29th, 2026

SESSION: Precision-Designed 3D Printed Inherent Particle Mimics for Visual Inspection System Qualification

◆  Conventional standards (polystyrene spheres, glass beads) poorly represent real parenteral particles in refractive index, morphology, and suspension behavior.

◆  Two-photon 3D printing enables precise tuning of particle size, shape, and optical properties to create more realistic standards.

◆  Standards can be tailored to mimic product-specific particles such as protein aggregates or cell clumps.

◆  Case study 1: protein-like model particles developed to qualify automated visual inspection instruments.

◆  Case study 2: cell clump mimics and suspension surrogates designed for cell therapy product inspection.

◆  Probability-of-detection studies were performed across varying particle sizes and matrices.

]]>
Robin Van Mechelen https://www.uventia.com/speaker/robin-van-mechelen/ Sat, 13 Jun 2026 06:58:11 +0000 https://www.uventia.com/?post_type=speaker&p=12881
Robin Van Mechelen

Robin Van Mechelen

Senior Process Engineer Visual Inspection & CCIT

eyetec

Robin Van Mechelen is a Senior Process Engineer Visual Inspection & CCIT at Eyetec, specializing in Visual Inspection and Container Closure Integrity Testing (CCIT) within the pharmaceutical industry. With over eight years of experience, he has developed strong expertise in automated, semi-automated and manual visual inspection processes, with a particular focus on qualification/validation and performance optimization.
He has played a key role in the implementation and qualification of Automated Visual Inspection (AVI) systems across multiple pharmaceutical manufacturing sites, supporting robust inspection strategies and alignment with regulatory expectations. He holds a Master’s degree in Industrial Engineering with a specialization in automation.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: AI and generative data for Visual Inspection

◆  AI usage in Visual Inspection.

◆  Annex 22: regulatory requirements.

◆  Practicle examples on AI usage in Visual Inspection.

]]>
Roman Mathaes https://www.uventia.com/speaker/roman-mathaes/ Thu, 11 Jun 2026 19:22:12 +0000 https://www.uventia.com/?post_type=speaker&p=12874
Roman Mathaes

Roman Mathaes

Chief Executive Officer

Clear-Solutions-Laboratories

Roman Mathaes is CEO of Clear Solutions Laboratories and a recognized expert in visual inspection and particle contamination control for injectable medicines. Previously, he held leadership roles at Roche/Genentech and served as Head of Pharmaceutical Services at Lonza, supporting global pharmaceutical development and manufacturing.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: A Roadmap for Implementation of Automated Visual Inspection for Parenteral Drug Products

Automated Visual Inspection (AVI) is increasingly adopted for sterile injectable drug products, but practical implementation guidance remains limited. This presentation proposes a pragmatic roadmap from equipment selection to inspection process performance qualification (iPPQ), with a focus on visual inspection (VI) test set requirements.

◆  Demonstrating AVI equivalence to Manual Visual Inspection (MVI) per USP <1790> and EU GMP Annex 1.

◆  Defining fit-for-purpose VI test sets throughout the AVI lifecycle.

◆  Common implementation pitfalls and mitigation strategies.

◆  Optimization of false reject rates (FRR) during vision engineering.

◆  Product bracketing considerations for AVI systems.

◆  Opportunities and limitations of artificial intelligence in AVI.

Special emphasis is placed on the critical role of VI test sets in qualification, performance verification, and lifecycle management to enable robust, compliant, and efficient AVI implementation.

]]>
Anthony Amato https://www.uventia.com/speaker/anthony-amato/ Thu, 11 Jun 2026 06:09:54 +0000 https://www.uventia.com/?post_type=speaker&p=12863
Anthony Amato

Anthony Amato

Amato-Product Development Manager

InQuest Science LLC

Anthony Amato joined InQuest Science in September 2021 as our Product Development Manager. Mr. Amato is responsible for the organization strategies through the effective direction and management of resources, while being accountable for the business strategies, functional or operational areas processes or programs. Responsible and accountable for managing, setting direction and deploying resources on varying projects. Participating in organization-wide projects, while providing guidance and expertise on an as needed basis. Design, develop, modify, adapt and implement solutions for information technology needs through new and existing applications, systems architecture and applications infrastructure.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: Session

◆  

◆  

◆  

]]>
Roy Cherris https://www.uventia.com/speaker/roy-cherris/ Thu, 11 Jun 2026 06:06:18 +0000 https://www.uventia.com/?post_type=speaker&p=12858
Roy Cherris

Roy Cherris

Cherris-Chief Science Officer

InQuest Science LLC

Roy Cherris has over 40 years of Quality Assurance experience. He is a founding member and Managing Partner of Bridge Associates International. He is also Chief Science Officer of InQuest Science. Mr. Cherris formerly served as the head of Microbiology Laboratories for Hoechst Marion Roussel and Aventis Pharmaceuticals. He is a well respected expert in the field of visual inspection systems and investigative microscopy for particle source identification and mitigation. His technical expertise includes visual Inspection, investigative microscopy, aseptic manufacturing, sterilization processes, environmental monitoring, microbiological testing, medical devices, laboratory and process development, as well as the qualification of equipment, facilities, and instrumentation. He has been certified by the New Jersey Pharmaceutical Quality Control Association in GxP, Good Manufacturing Practices. Mr. Cherris has worked internationally throughout the Americas, Australia, Europe and Asia. Mr. Cherris has a B.S.c. degree in Life Sciences with concentration in Microbiology and has studied forensic microscopy extensively at the McCrone Research Institute in Chicago. His current publication is the technical book titled “Visual Inspection and Particulate Control” 2016, Davis Healthcare International Publishing. Mr. Cherris has served as a member of the PDA task force on Visual Inspection since 1998, and has been an active member of the USP Expert Panel for Visual Inspection of parenterals since 2009. His professional activities have included various technical committees in ASQ, ASTM, ISPE, PhRMA(PMA), PDA, American Society for Microbiology, Institute of Environmental Sciences, and the United States Pharmacopeia.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 1: September 28th, 2026

SESSION: Session

◆  

◆  

◆  

]]>
Callum Leonard https://www.uventia.com/speaker/callum-leonard/ Fri, 05 Jun 2026 10:06:11 +0000 https://www.uventia.com/?post_type=speaker&p=12822
Callum Leonard

Callum Leonard

Director & AVI SME

Valisense

Callum Leonard is Founder of Valisense, a consulting firm focused on Automated Visual Inspection (AVI) implementation and optimization in regulated manufacturing.Previously involved in early-stage software startup, contributing to product development, system architecture, and scaling technical solutions.Background in Computer Science and software engineering. Leads end to end deployment of AVI systems, from requirements definition through validation and production rollout.

Speaked About
September 28, 2026
The 2nd Annual Visual Inspection in Parenterals Summit covers regulatory trends, AI advancements, and strategies for sterile manufacturing.
Upcoming

DAY 2: September 29th, 2026

SESSION: The Hidden Complexity of AVI: Why Good Systems Fail in Real Production

◆  Hidden hurdles in AVI implementation.

◆  Why false rejects and variability derail projects.

◆  The gap between pilot success and production reality.

◆  Validation, data, and ownership as critical success factors.

◆  How to make AVI robust in real manufacturing environments.

]]>